WallStreetZenWallStreetZen

NASDAQ: BIOA
Bioage Labs Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BIOA

Based on 3 analysts offering 12 month price targets for Bioage Labs Inc

Min Forecast
$5.00+24.38%
Avg Forecast
$5.67+40.97%
Max Forecast
$7.00+74.13%

Should I buy or sell BIOA stock?

Based on 3 analysts offering ratings for Bioage Labs Inc.

Sell
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
2 analysts 66.67%
Sell
0 analysts 0%
Strong Sell
1 analysts 33.33%
Our proven Zen Rating quant model agrees with analyst consensus with a "Sell" rating. Learn More

Be the first to know when Wall Street analysts revise their BIOA stock forecasts and price targets.

BIOA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-24
lockedlocked$00.00+00.00%2025-03-07
lockedlocked$00.00+00.00%2024-12-09

1 of 1

Forecast return on equity

Is BIOA forecast to generate an efficient return?

Company
-19.75%
Industry
44.61%
Market
81.87%
BIOA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BIOA forecast to generate an efficient return on assets?

Company
-17.81%
Industry
15.28%
BIOA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BIOA earnings per share forecast

What is BIOA's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$2.03
Avg 2 year Forecast
-$1.98
Avg 3 year Forecast
-$2.34

BIOA revenue forecast

What is BIOA's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$24.9M

BIOA vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
BIOA$4.02$5.67+40.97%Sell
DERM$6.33N/AN/A
CGC$1.08N/AN/A
OGI$1.00N/AN/A
ESPR$0.85$6.67+682.51%Buy
View Top Pharmaceutical Stocks

Bioage Labs Stock Forecast FAQ

Is Bioage Labs Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: BIOA) stock is to Sell BIOA stock.

Out of 3 analysts, 0 (0%) are recommending BIOA as a Strong Buy, 0 (0%) are recommending BIOA as a Buy, 2 (66.67%) are recommending BIOA as a Hold, 0 (0%) are recommending BIOA as a Sell, and 1 (33.33%) are recommending BIOA as a Strong Sell.

If you're new to stock investing, here's how to buy Bioage Labs stock.

What is BIOA's earnings growth forecast for 2025-2027?

(NASDAQ: BIOA) Bioage Labs's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 23.44%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.

Bioage Labs's earnings in 2025 is -$71,109,000.On average, 3 Wall Street analysts forecast BIOA's earnings for 2025 to be -$72,775,575, with the lowest BIOA earnings forecast at -$105,757,609, and the highest BIOA earnings forecast at -$54,133,556. On average, 3 Wall Street analysts forecast BIOA's earnings for 2026 to be -$70,983,073, with the lowest BIOA earnings forecast at -$110,418,114, and the highest BIOA earnings forecast at -$42,303,044.

In 2027, BIOA is forecast to generate -$83,889,087 in earnings, with the lowest earnings forecast at -$105,757,609 and the highest earnings forecast at -$62,020,564.

What is BIOA's revenue growth forecast for 2030-2030?

(NASDAQ: BIOA) Bioage Labs's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.

Bioage Labs's revenue in 2025 is $0.

In 2030, BIOA is forecast to generate $892,665,921 in revenue, with the lowest revenue forecast at $892,665,921 and the highest revenue forecast at $892,665,921.

What is BIOA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: BIOA) forecast ROA is -17.81%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 15.28%.

What is BIOA's Price Target?

According to 3 Wall Street analysts that have issued a 1 year BIOA price target, the average BIOA price target is $5.67, with the highest BIOA stock price forecast at $7.00 and the lowest BIOA stock price forecast at $5.00.

On average, Wall Street analysts predict that Bioage Labs's share price could reach $5.67 by Mar 24, 2026. The average Bioage Labs stock price prediction forecasts a potential upside of 40.97% from the current BIOA share price of $4.02.

What is BIOA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: BIOA) Bioage Labs's current Earnings Per Share (EPS) is -$6.63. On average, analysts forecast that BIOA's EPS will be -$2.03 for 2025, with the lowest EPS forecast at -$2.95, and the highest EPS forecast at -$1.51. On average, analysts forecast that BIOA's EPS will be -$1.98 for 2026, with the lowest EPS forecast at -$3.08, and the highest EPS forecast at -$1.18. In 2027, BIOA's EPS is forecast to hit -$2.34 (min: -$2.95, max: -$1.73).

What is BIOA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: BIOA) forecast ROE is -19.75%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.